Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| VERACYTE, INC.VCYT · Entity 2018 | VP, Chief Accounting Officer | September 02, 2026 | September 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
VERACYTE, INC.
Report date September 02, 2026 · Filed September 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 43,226 |
Reported balance
After 2026-09-02 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-02 · Tax withholding · Disposed 1,361 · Balance 43,226 F1: Represents shares of common stock withheld to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of certain restricted stock units on September 2, 2026 and does not represent a sale. F2: Includes 514 shares of common stock purchased on July 31, 2026 pursuant to the Veracyte, Inc. Employee Stock Purchase Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock withheld to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of certain restricted stock units on September 2, 2026 and does not represent a sale.
F2: Includes 514 shares of common stock purchased on July 31, 2026 pursuant to the Veracyte, Inc. Employee Stock Purchase Plan.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ALERE INC.
Report date October 03, 2017 · Filed October 03, 2017
Section 16 reporting ended · disclosed 2017-10-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-10-03 transaction · row 1
1 source rowRow 1 · 2017-10-03 · Disposition to issuer · Disposed 1,909 · Balance 0 F1: Pursuant to that certain Agreement and Plan of Merger, dated as of January 30, 2016, as amended on April 13, 2017 (the "Merger Agreement"), between Alere Inc. (the "Company") and Abbott Laboratories, at the Effective Time (as defined in the Merger Agreement) (the "Effective Time"), each of these shares of the Company's common stock (the "Common Stock") was converted into the right to receive $51.00 (the "Merger Consideration"). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2017-10-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-10-03 · Disposition to issuer · Disposed 6,666 · Balance 0 F2: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to that certain Agreement and Plan of Merger, dated as of January 30, 2016, as amended on April 13, 2017 (the "Merger Agreement"), between Alere Inc. (the "Company") and Abbott Laboratories, at the Effective Time (as defined in the Merger Agreement) (the "Effective Time"), each of these shares of the Company's common stock (the "Common Stock") was converted into the right to receive $51.00 (the "Merger Consideration").
F2: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 02, 2026 Filed Sep 4, 2026 23:54 UTC | VERACYTE, INC. VCYT · Entity 2018 | Tax withholdingCommon Stock | 1,361 | $44.88 | $61,081.68 |
DisclosureSEC source: 0001584145-26-000009 · wk-form4_1788566062.xml · nonDerivative · entry 1 Wygant Jonathan · CIK 0001584145 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,226 F1 · kind: Represents shares of common stock withheld to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of certain restricted stock units on September 2, 2026 and does not represent a sale. F2 · balance_after: Includes 514 shares of common stock purchased on July 31, 2026 pursuant to the Veracyte, Inc. Employee Stock Purchase Plan. Read SEC document |
| June 02, 2026 Filed Jun 5, 2026 01:38 UTC | VERACYTE, INC. VCYT · Entity 2018 | Tax withholdingCommon Stock | 1,361 | $47.80 | $65,055.80 |
DisclosureSEC source: 0001584145-26-000007 · wk-form4_1780623524.xml · nonDerivative · entry 1 Wygant Jonathan · CIK 0001584145 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,073 F1 · kind: Represents shares of common stock withheld to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of certain restricted stock units on June 2, 2026 and does not represent a sale. Read SEC document |
| May 22, 2026 Filed May 27, 2026 20:19 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 24,000 | $0.00 Strike: $24.80 | $0.00 |
DisclosureSEC source: 0001584145-26-000006 · wk-form4_1779913148.xml · derivative · entry 3 Wygant Jonathan · CIK 0001584145 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,000 shares Expires 2032-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is fully vested. Read SEC document |
| May 22, 2026 Filed May 27, 2026 20:19 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 24,000 | $45.40 | $1,089,624.00 |
DisclosureSEC source: 0001584145-26-000006 · wk-form4_1779913148.xml · nonDerivative · entry 2 Wygant Jonathan · CIK 0001584145 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,434 F1 · price: Represents weighted average sales price. Sale prices for the transactions range from $45.07 to $45.69. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| May 22, 2026 Filed May 27, 2026 20:19 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 24,000 | $24.80 | $595,200.00 |
DisclosureSEC source: 0001584145-26-000006 · wk-form4_1779913148.xml · nonDerivative · entry 1 Wygant Jonathan · CIK 0001584145 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,434 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 06, 2026 Filed Mar 10, 2026 21:10 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantCommon Stock | 10,525 | $0.00 | $0.00 |
DisclosureSEC source: 0001584145-26-000004 · wk-form4_1773177026.xml · nonDerivative · entry 1 Wygant Jonathan · CIK 0001584145 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,434 F1 · kind: Restricted stock units awarded on March 6, 2026 vest 25% on March 2, 2027 and 1/16 per quarter thereafter subject to continuing employment of the Reporting Person on each vesting date. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 21:17 UTC | VERACYTE, INC. VCYT · Entity 2018 | Tax withholdingCommon Stock | 3,006 | $36.01 | $108,246.06 |
DisclosureSEC source: 0001584145-26-000002 · wk-form4_1772659020.xml · nonDerivative · entry 1 Wygant Jonathan · CIK 0001584145 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,909 F1 · kind: Represents shares of common stock withheld to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of certain restricted stock units on March 2, 2026 and does not represent a sale. F2 · balance_after: Includes 495 shares of common stock purchased on January 31, 2026 pursuant to the Veracyte, Inc. Employee Stock Purchase Plan. Read SEC document |
| December 02, 2025 Filed Dec 5, 2025 00:43 UTC | VERACYTE, INC. VCYT · Entity 2018 | Tax withholdingCommon Stock | 1,325 | $46.16 | $61,162.00 |
DisclosureSEC source: 0001584145-25-000010 · wk-form4_1764895427.xml · nonDerivative · entry 1 Wygant Jonathan · CIK 0001584145 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,420 F1 · kind: Represents shares of common stock withheld to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of certain restricted stock units on December 2, 2025 and does not represent a sale. Read SEC document |
| November 10, 2025 Filed Nov 12, 2025 21:25 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 5,102 | $42.33 | $215,978.37 |
DisclosureSEC source: 0001584145-25-000008 · wk-form4_1762982744.xml · nonDerivative · entry 2 Wygant Jonathan · CIK 0001584145 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,745 F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $42.2866 to $42.4436. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| November 07, 2025 Filed Nov 12, 2025 21:25 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 5,818 | $40.21 | $233,928.98 |
DisclosureSEC source: 0001584145-25-000008 · wk-form4_1762982744.xml · nonDerivative · entry 1 Wygant Jonathan · CIK 0001584145 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,847 F1 · price: Represents weighted average sales price. Sale prices for the transactions range from $40.06 to $40.958. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| October 28, 2025 Filed Oct 30, 2025 20:39 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantCommon Stock | 2,886 | $0.00 | $0.00 |
DisclosureSEC source: 0001584145-25-000006 · wk-form4_1761856769.xml · nonDerivative · entry 1 Wygant Jonathan · CIK 0001584145 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,665 F1 · kind: Restricted stock units awarded on October 28, 2025 vest in full on the first anniversary of the grant date subject to continuing employment of the Reporting Person. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 21:05 UTC | VERACYTE, INC. VCYT · Entity 2018 | Tax withholdingCommon Stock | 1,648 | $30.11 | $49,621.28 |
DisclosureSEC source: 0001384101-25-000112 · wk-form4_1757019956.xml · nonDerivative · entry 1 Wygant Jonathan · CIK 0001584145 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,779 F1 · kind: Represents shares of common stock withheld to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of certain restricted stock units on September 2, 2025 and does not represent a sale. F2 · balance_after: Includes 512 shares of common stock purchased on July 30, 2025 pursuant to the Veracyte, Inc. Employee Stock Purchase Plan. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 21:01 UTC | VERACYTE, INC. VCYT · Entity 2018 | Tax withholdingCommon Stock | 1,848 | $26.74 | $49,415.52 |
DisclosureSEC source: 0001384101-25-000069 · wk-form4_1749070851.xml · nonDerivative · entry 1 Wygant Jonathan · CIK 0001584145 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,915 F1 · kind: The reporting person is reporting the withholding of 381, 363, 344 and 760 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 750, 713, 677 and 1,496 Restricted Stock Units granted on February 22, 2022, August 5, 2022, March 6, 2023 and March 6, 2024, respectively, and does not represent a sale by the reporting person. Read SEC document |
| March 06, 2025 Filed Mar 10, 2025 20:44 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantCommon Stock | 13,288 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-25-000045 · wk-form4_1741639458.xml · nonDerivative · entry 1 Wygant Jonathan · CIK 0001584145 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,763 F1 · kind: Restricted stock units awarded on March 6, 2025 vest 25% on March 2, 2026 and 1/16 per quarter thereafter subject to continuing employment of the Reporting Person on each vesting date. Read SEC document |
| March 02, 2025 Filed Mar 3, 2025 21:30 UTC | VERACYTE, INC. VCYT · Entity 2018 | Tax withholdingCommon Stock | 4,301 | $34.76 | $149,502.76 |
DisclosureSEC source: 0001384101-25-000023 · wk-form4_1741037413.xml · nonDerivative · entry 1 Wygant Jonathan · CIK 0001584145 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,475 F1 · kind: The reporting person is reporting the withholding of 421, 401, 381 and 3,098 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 750, 714, 678 and 5,985 Restricted Stock Units granted on February 22, 2022, August 5, 2022, March 6, 2023 and March 6, 2024, respectively, and does not represent a sale by the reporting person. F2 · balance_after: Includes 506 shares of common stock purchased pursuant to the Veracyte, Inc. Employee Stock Purchase Plan. Read SEC document |
| December 03, 2024 Filed Dec 4, 2024 21:59 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 956 | $43.36 | $41,452.45 |
DisclosureSEC source: 0001384101-24-000178 · wk-form4_1733349540.xml · nonDerivative · entry 2 Wygant Jonathan · CIK 0001584145 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,270 Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 21:59 UTC | VERACYTE, INC. VCYT · Entity 2018 | Tax withholdingCommon Stock | 1,087 | $44.12 | $47,958.44 |
DisclosureSEC source: 0001384101-24-000178 · wk-form4_1733349540.xml · nonDerivative · entry 1 Wygant Jonathan · CIK 0001584145 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,226 F1 · kind: The reporting person is reporting the withholding of 381, 362, and 344 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 750, 713, and 677 Restricted Stock Units granted on February 22, 2022, August 5, 2022, and March 6, 2023, respectively, and does not represent a sale by the reporting person. Read SEC document |
| November 27, 2024 Filed Nov 29, 2024 19:28 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 5,032 | $42.89 | $215,833.55 |
DisclosureSEC source: 0001384101-24-000170 · wk-form4_1732908520.xml · nonDerivative · entry 1 Wygant Jonathan · CIK 0001584145 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,313 F1 · price: Represents weighted average sales price. Sale prices for the transactions range from $42.8028 to $42.9001. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| September 02, 2024 Filed Sep 4, 2024 22:08 UTC | VERACYTE, INC. VCYT · Entity 2018 | Tax withholdingCommon Stock | 1,087 | $31.55 | $34,294.85 |
DisclosureSEC source: 0001384101-24-000148 · wk-form4_1725484107.xml · nonDerivative · entry 1 Wygant Jonathan · CIK 0001584145 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,345 F1 · kind: The reporting person is reporting the withholding of 381, 362, and 344 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 750, 713, and 678 Restricted Stock Units granted on February 22, 2022, August 5, 2022, and March 6, 2023, respectively, and does not represent a sale by the reporting person. F2 · balance_after: Includes 461 shares of common stock purchased pursuant to the Veracyte, Inc. Employee Stock Purchase Plan. Read SEC document |
| June 02, 2024 Filed Jun 4, 2024 20:42 UTC | VERACYTE, INC. VCYT · Entity 2018 | Tax withholdingCommon Stock | 1,087 | $20.75 | $22,555.25 |
DisclosureSEC source: 0001384101-24-000075 · wk-form4_1717533745.xml · nonDerivative · entry 1 Wygant Jonathan · CIK 0001584145 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,971 F1 · kind: The reporting person is reporting the withholding of 381, 362, and 344 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 750, 714, and 677 Restricted Stock Units granted on February 22, 2022, August 5, 2022, and March 6, 2023, respectively, and does not represent a sale by the reporting person. Read SEC document |
| March 06, 2024 Filed Mar 8, 2024 21:36 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantCommon Stock | 23,942 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-24-000038 · wk-form4_1709933802.xml · nonDerivative · entry 1 Wygant Jonathan · CIK 0001584145 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,058 F1 · kind: Restricted stock units awarded on March 6, 2024 vest 25% on March 2, 2025 and 1/16 per quarter thereafter subject to continuing employment of the Reporting Person on each vesting date. Read SEC document |
| March 02, 2024 Filed Mar 5, 2024 22:29 UTC | VERACYTE, INC. VCYT · Entity 2018 | Tax withholdingCommon Stock | 2,337 | $24.00 | $56,088.00 |
DisclosureSEC source: 0001384101-24-000028 · wk-form4_1709677724.xml · nonDerivative · entry 1 Wygant Jonathan · CIK 0001584145 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,116 F1 · kind: The reporting person is reporting the withholding of 420, 400, and 1,517 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 750, 713, and 2,709 Restricted Stock Units granted on February 22, 2022, August 5, 2022, and March 6, 2023, respectively, and does not represent a sale by the reporting person. F2 · balance_after: Includes 433 shares of common stock purchased pursuant to the Veracyte, Inc. Employee Stock Purchase Plan. Read SEC document |
| December 02, 2023 Filed Dec 5, 2023 21:45 UTC | VERACYTE, INC. VCYT · Entity 2018 | Tax withholdingCommon Stock | 507 | $26.54 | $13,455.78 |
DisclosureSEC source: 0001384101-23-000172 · wk-form4_1701812717.xml · nonDerivative · entry 1 Wygant Jonathan · CIK 0001584145 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,020 F1 · kind: The reporting person is reporting the withholding of 260 and 247 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 750 and 713 Restricted Stock Units granted on February 22, 2022 and August 5, 2022, respectively, and does not represent a sale by the reporting person. Read SEC document |
| September 02, 2023 Filed Sep 6, 2023 20:31 UTC | VERACYTE, INC. VCYT · Entity 2018 | Tax withholdingCommon Stock | 1,247 | $26.70 | $33,294.90 |
DisclosureSEC source: 0001384101-23-000148 · wk-form4_1694032286.xml · nonDerivative · entry 1 Wygant Jonathan · CIK 0001584145 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,527 F1 · kind: The reporting person is reporting the withholding of 260 and 987 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 750 and 2,854 Restricted Stock Units granted on February 22, 2022 and August 5, 2022, respectively, and does not represent a sale by the reporting person. F2 · balance_after: Includes 420 shares of common stock purchased pursuant to the Veracyte, Inc. Employee Stock Purchase Plan. Read SEC document |
| June 02, 2023 Filed Jun 6, 2023 20:49 UTC | VERACYTE, INC. VCYT · Entity 2018 | Tax withholdingCommon Stock | 260 | $26.72 | $6,947.20 |
DisclosureSEC source: 0001384101-23-000083 · wf-form4_168608454360999.xml · nonDerivative · entry 1 Wygant Jonathan · CIK 0001584145 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,354 F1 · kind: The reporting person is reporting the withholding of 260 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 750 Restricted Stock Units granted on February 22, 2022 and does not represent a sale by the reporting person. Read SEC document |
| March 06, 2023 Filed Mar 10, 2023 00:09 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantStock Option (right to buy) · Derivative | 14,213 | $0.00 Strike: $23.73 | $0.00 |
DisclosureSEC source: 0001384101-23-000036 · wf-form4_167840698540045.xml · derivative · entry 2 Wygant Jonathan · CIK 0001584145 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,213 Underlying: Common Stock · 14,213 shares Expires 2033-03-06 F2 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on March 2, 2024, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| March 06, 2023 Filed Mar 10, 2023 00:09 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantCommon Stock | 8,868 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-23-000036 · wf-form4_167840698540045.xml · nonDerivative · entry 1 Wygant Jonathan · CIK 0001584145 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,614 F1 · kind: Restricted stock units awarded on March 6, 2023 vest 25% on March 2, 2024 and 1/16 per quarter thereafter subject to continuing employment of the Reporting Person on each vesting date. Read SEC document |
| March 02, 2023 Filed Mar 4, 2023 01:10 UTC | VERACYTE, INC. VCYT · Entity 2018 | Tax withholdingCommon Stock | 1,224 | $24.10 | $29,498.40 |
DisclosureSEC source: 0001384101-23-000027 · wf-form4_167789219870703.xml · nonDerivative · entry 1 Wygant Jonathan · CIK 0001584145 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,746 F1 · kind: The reporting person is reporting the withholding of 1,224 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 3,000 Restricted Stock Units granted on February 22, 2022 and does not represent a sale by the reporting person. F2 · balance_after: Includes 409 shares of common stock purchased on January 31, 2023 pursuant to the Veracyte, Inc. Employee Stock Purchase Plan. Read SEC document |
| August 05, 2022 Filed Aug 9, 2022 21:18 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantStock Option (right to buy) · Derivative | 14,598 | $0.00 Strike: $27.90 | $0.00 |
DisclosureSEC source: 0001384101-22-000116 · wf-form4_166007984477764.xml · derivative · entry 2 Wygant Jonathan · CIK 0001584145 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,598 Underlying: Common Stock · 14,598 shares Expires 2032-08-05 F2 · derivative.exercise_date: The option becomes exercisable as to 1/3rd of the shares on August 5, 2023, and the remaining shares vest at a rate of 1/36th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| August 05, 2022 Filed Aug 9, 2022 21:18 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantCommon Stock | 8,561 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-22-000116 · wf-form4_166007984477764.xml · nonDerivative · entry 1 Wygant Jonathan · CIK 0001584145 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,561 F1 · kind: Restricted stock units awarded on August 5, 2022 vest 1/3rd on September 2, 2023 and 1/12th per quarter thereafter subject to continuing employment of the Reporting Person on each vesting date. Read SEC document |
| October 03, 2017 Filed Oct 3, 2017 17:42 UTC | ALERE INC. ALR · Entity 172772 | Disposition to issuerRestricted Stock Units · Derivative | 6,666 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950142-17-001798 · es1701022_4-wygant.xml · derivative · entry 2 Wygant Jonathan · CIK 0001584145 · VP, Controller, CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,666 shares Expires not disclosed F2 · derivative.exercise_price: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option. F2 · price: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option. F2 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option. Read SEC document |
| October 03, 2017 Filed Oct 3, 2017 17:42 UTC | ALERE INC. ALR · Entity 172772 | Disposition to issuerCommon Stock | 1,909 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950142-17-001798 · es1701022_4-wygant.xml · nonDerivative · entry 1 Wygant Jonathan · CIK 0001584145 · VP, Controller, CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to that certain Agreement and Plan of Merger, dated as of January 30, 2016, as amended on April 13, 2017 (the "Merger Agreement"), between Alere Inc. (the "Company") and Abbott Laboratories, at the Effective Time (as defined in the Merger Agreement) (the "Effective Time"), each of these shares of the Company's common stock (the "Common Stock") was converted into the right to receive $51.00 (the "Merger Consideration"). Read SEC document |
| January 15, 2017 Filed Jan 17, 2017 17:51 UTC | ALERE INC. ALR · Entity 172772 | Exercise / conversionRestricted Stock Units · Derivative | 3,334 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-000975 · edgar.xml · derivative · entry 3 Wygant Jonathan · CIK 0001584145 · VP, Controller, CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,666 Underlying: Common Stock · 3,334 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Alere common stock. F2 · derivative.exercise_date: The restricted stock units will vest as follows: one-third on the first anniversary of the grant date (1/15/17); one-third on the second anniversary of the grant date (1/15/18); and one-third on the third anniversary of the grant date (1/15/19). F2 · derivative.expiration_date: The restricted stock units will vest as follows: one-third on the first anniversary of the grant date (1/15/17); one-third on the second anniversary of the grant date (1/15/18); and one-third on the third anniversary of the grant date (1/15/19). Read SEC document |
| January 15, 2017 Filed Jan 17, 2017 17:51 UTC | ALERE INC. ALR · Entity 172772 | Tax withholdingCommon Stock | 1,425 | $39.89 | $56,843.25 |
DisclosureSEC source: 0001179110-17-000975 · edgar.xml · nonDerivative · entry 2 Wygant Jonathan · CIK 0001584145 · VP, Controller, CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,909 Read SEC document |
| January 15, 2017 Filed Jan 17, 2017 17:51 UTC | ALERE INC. ALR · Entity 172772 | Exercise / conversionCommon Stock | 3,334 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-17-000975 · edgar.xml · nonDerivative · entry 1 Wygant Jonathan · CIK 0001584145 · VP, Controller, CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,334 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Alere common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.